Influenza Diagnostics Market worth $1.1 billion by 2026 – Exclusive Report by MarketsandMarkets™

Northbrook, IL, USA, 2021-Nov-25 — /EPR Network/ —

According to the new market research report “Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026″, published by MarketsandMarkets™, the global Influenza Diagnostics Market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7%.

Browse in-depth TOC on “Influenza Diagnostics Market”
154 – Tables
41 – Figures
193 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222985562

The Rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the market.

The test kits and reagents segment accounted for the largest share of the traditional diagnostic tests market, by product segment, in 2020

Based on product and service, the influenza diagnostics market is segmented into test kits and reagents, instruments and other products. The test kits and reagents segment accounted for the largest share of the traditional diagnostic tests market in 2020. Factors such as growth in influenza research for diagnostic technologies and increasing prevalence of influenza are contributing for the growth of this market.

Molecular Diagnostic Tests segment to register the highest growth rate during the forecast period

The influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate. Factors such as the rising demand for rapid disease diagnosis drive this market and growth in influenza research for diagnostic technologies.

The diagnostic laboratories segment accounted for the largest share of the influenza diagnostics market, by end user segment, in 2020

Based on end user, the market has been segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the traditional diagnostic tests market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis is driving this segments growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222985562

North America is the largest regional market for influenza diagnostics market

The global market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the influenza diagnostics market. The large share of this region can be attributed to growth in influenza research for diagnostic technologies and rising demand for rapid disease diagnosis.

The major players operating in this traditional diagnostic tests market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecanclinica Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India).